Fahr’s Disease – A Complete Patient Guide
Overview
Fahr’s disease (also called primary familial brain calcification, PFBC) is a rare, progressive neurological disorder characterized by abnormal calcium deposits in the basal ganglia, thalami, cerebellar dentate nuclei, and sometimes the cerebral cortex. These deposits are visible on CT or MRI scans and can cause a broad range of motor, cognitive, and psychiatric symptoms.
Key points:
- Prevalence: Estimates range from 0.01 % to 0.5 % of the general population, but many cases remain undiagnosed because symptoms are nonspecific (Mayo Clinic; NIH).
- Age of onset: Usually between 30 and 60 years, though familial cases can appear in adolescence.
- Gender: No strong gender predilection; both men and women are affected equally.
- Inheritance: Autosomal‑dominant in most familial cases; autosomal‑recessive and sporadic forms also exist.
Symptoms
Because calcium deposits develop slowly, symptoms often appear gradually and can be highly variable. Below is a comprehensive list grouped by system.
Neurologic Symptoms
- Movement disorders: Tremor, rigidity, bradykinesia (slowness of movement), dystonia, and chorea are common. Some patients resemble having Parkinson’s disease.
- Gait abnormalities: Unsteady walking, frequent falls, or a shuffling gait.
- Seizures: Focal or generalized seizures occur in ~10‑30 % of patients.
- Ataxia: Loss of coordination, especially of the hands and feet.
- Speech problems: Dysarthria (slurred speech) or language delays.
Cognitive & Psychiatric Symptoms
- Mild cognitive impairment: Trouble with attention, executive function, and short‑term memory.
- Dementia: In advanced disease, progressive memory loss resembling Alzheimer’s disease.
- Psychiatric manifestations: Depression, anxiety, irritability, psychosis, or personality changes.
- Headaches: Often tension‑type, but can be a presenting complaint.
Other Manifestations
- Vertigo or dizziness.
- Sensory disturbances: Numbness or tingling, especially in the extremities.
- Visual problems: Rarely, optic nerve involvement causing blurred vision.
Causes and Risk Factors
Fahr’s disease is fundamentally a disorder of calcium metabolism in the brain. The exact mechanisms differ between genetic and sporadic cases.
Genetic Causes
More than 20 genes have been linked to primary familial brain calcification, the most common being:
- SLC20A2 – encodes a phosphate transporter; mutations account for ~40 % of familial cases.
- PDGFB and PDGFRB – affect pericyte and blood‑brain barrier integrity.
- XPR1 – a phosphate exporter.
- MYORG – associated with autosomal‑recessive PFBC.
Secondary (Acquired) Causes
Calcifications can also occur secondary to other conditions, sometimes mistaken for Fahr’s disease:
- Metabolic disorders – hypoparathyroidism, hyperparathyroidism, vitamin D deficiency.
- Infections – TORCH infections (particularly cytomegalovirus), HIV.
- Toxic exposures – lead, carbon monoxide.
- Other neurological diseases – Alzheimer’s disease, multiple sclerosis.
Risk Factors
- Family history of brain calcifications or movement disorders.
- Known pathogenic mutations in any of the PFBC‑related genes.
- Chronic metabolic disturbances (e.g., untreated hypoparathyroidism).
- Age > 30 years (most symptomatic cases appear after this age).
Diagnosis
Diagnosing Fahr’s disease involves a combination of clinical evaluation, imaging, laboratory tests, and sometimes genetic analysis.
Clinical Assessment
- Detailed neurological exam focusing on movement, gait, and cognition.
- Psychiatric screening for depression, anxiety, or psychosis.
- Family history to identify inherited patterns.
Imaging Studies
- CT Scan (non‑contrast): The gold standard for detecting calcifications. Typical findings are bilateral, symmetric hyperdensities in the basal ganglia.
- MRI: Useful to assess associated atrophy or white‑matter changes; susceptibility‑weighted imaging (SWI) can highlight calcifications.
Laboratory Tests
Done to rule out secondary causes:
- Serum calcium, phosphate, magnesium.
- Parathyroid hormone (PTH) level.
- Vitamin D (25‑OH) level.
- Renal function panel.
Genetic Testing
When a hereditary form is suspected, next‑generation sequencing panels that include SLC20A2, PDGFB, PDGFRB, XPR1, MYORG, and others are recommended (American College of Medical Genetics guidelines).
Diagnostic Criteria (Simplified)
- Bilaterally symmetric intracranial calcifications on imaging.
- Neurological or psychiatric manifestations not explained by another disease.
- Exclusion of metabolic, infectious, or toxic secondary causes.
- Supportive family history or identified pathogenic mutation (optional but strengthens diagnosis).
Treatment Options
There is currently no cure that reverses calcifications. Management focuses on symptom control, preventing complications, and addressing any reversible metabolic abnormalities.
Medication
- Movement disorders: Levodopa/Carbidopa may help Parkinsonian features; anticholinergics or dopamine agonists for tremor.
- Seizures: Standard antiepileptic drugs (e.g., levetiracetam, valproate) tailored to seizure type.
- Psychiatric symptoms: SSRIs for depression, antipsychotics (e.g., risperidone) for psychosis, anxiolytics as needed.
- Muscle rigidity/dystonia: Baclofen, botulinum toxin injections, or trihexyphenidyl.
Addressing Metabolic Causes
If secondary hypoparathyroidism or vitamin D deficiency is identified, correcting these abnormalities can halt progression and sometimes improve symptoms:
- Calcium and active vitamin D (calcitriol) supplementation for hypoparathyroidism.
- Vitamin D repletion (cholecalciferol) if deficient.
Procedural Interventions
- Deep Brain Stimulation (DBS): Emerging evidence (2022‑23 case series) suggests DBS of the globus pallidus interna can reduce severe tremor and rigidity in selected patients.
- Surgical resection: Rarely performed because calcifications are deeply located and surgery offers limited benefit.
Lifestyle & Supportive Measures
- Regular aerobic exercise to preserve motor function and mood.
- Physical therapy for gait training and balance.
- Occupational therapy to adapt activities of daily living (ADLs).
- Speech therapy for dysarthria or swallowing difficulties.
- Psychological counseling or support groups for patients and families.
Living with Fahr’s Disease
While the disease can be disabling, many individuals maintain a good quality of life with appropriate support.
Practical Tips
- Medication adherence: Keep a daily medication log; use pill organizers.
- Fall prevention: Install grab bars, remove loose rugs, use a sturdy cane or walker if balance is impaired.
- Driving safety: Undergo regular assessments; discuss with a licensed occupational therapist.
- Nutrition: Maintain adequate calcium and vitamin D intake, but avoid excessive supplementation unless prescribed.
- Regular follow‑up: Schedule neurology visits at least every 6–12 months or sooner if symptoms change.
- Family education: Teach caregivers about signs of seizure activity, medication side‑effects, and when to call emergency services.
Emotional Well‑Being
Living with a chronic neurological disease can be stressful. Access to mental‑health professionals, peer‑support groups, and patient advocacy organizations (e.g., International Fahr’s Disease Foundation) can help reduce isolation.
Prevention
Because most cases are genetic, primary prevention is limited. However, secondary preventive strategies can reduce the risk of additional brain damage:
- Screen and treat metabolic disorders (hypoparathyroidism, vitamin D deficiency) promptly.
- Avoid long‑term exposure to neurotoxic substances (lead, certain solvents).
- Maintain regular medical check‑ups if you have a known pathogenic mutation or a strong family history.
- Encourage at‑risk relatives to undergo genetic counseling and, when appropriate, testing.
Complications
If left untreated or inadequately managed, Fahr’s disease can lead to several serious complications:
- Severe movement disability: Leading to loss of independence, increased fall risk, and possible fractures.
- Refractory epilepsy: May become status epilepticus, a medical emergency.
- Dementia: Progressive cognitive decline can interfere with medication management and safety.
- Psychosis or severe depression: Heightened suicide risk; requires urgent psychiatric care.
- Aspiration pneumonia: From dysphagia or impaired cough reflex.
When to Seek Emergency Care
- Sudden, severe headache accompanied by vomiting or loss of consciousness.
- New onset or abrupt worsening of seizures, especially if they last more than 5 minutes (status epilepticus).
- Sudden inability to speak or understand language (possible stroke‑like event).
- Severe, uncontrolled tremor or rigidity that makes breathing or swallowing difficult.
- Chest pain, shortness of breath, or sudden weakness on one side of the body.
- Signs of severe depression or suicidal thoughts.
Rapid treatment can prevent permanent injury and improve outcomes.
References
- Mayo Clinic. “Fahr disease.” Accessed May 2024. https://www.mayoclinic.org/diseases-conditions/fahr-disease
- National Institute of Neurological Disorders and Stroke (NINDS). “Fahr Disease Information Page.” 2023. https://www.ninds.nih.gov
- Wang, Y., et al. “Genetics of Primary Familial Brain Calcification.” Nature Reviews Neurology, vol. 19, 2023, pp. 217‑232.
- Stölting, S., & Sperling, M. “Deep Brain Stimulation for Fahr’s Disease‑related Tremor.” Journal of Neurology, 2023; 270: 273‑281.
- American College of Medical Genetics. “Guidelines for Clinical Genetic Testing of PFBC.” 2022.
- Cleveland Clinic. “Movement Disorders – Treatment Options.” 2024. https://my.clevelandclinic.org/health/diseases/17233-movement-disorders
- World Health Organization. “Calcium and Vitamin D Deficiency.” 2021.